Su Wen-Lin, Perng Wann-Cherng, Huang Ching-Hui, Yang Cheng-Yu, Wu Chin-Pyng, Chen Jenn-Han
Graduate Institute of Medical Sciences, National Defense Medical Center, No.161, Sec. 6, Mincyuan E. Rd., Neihu District, Taipei City 114, Taiwan, Republic of China.
Clin Vaccine Immunol. 2010 Feb;17(2):223-31. doi: 10.1128/CVI.00381-09. Epub 2009 Dec 9.
Mycobacterium tuberculosis infection is a major world health issue. The early identification of patients at risk for a poor response to anti-M. tuberculosis therapy would help elucidate the key players in the anti-M. tuberculosis response. The objective of the present study was to correlate the modulation of cytokine expression (interleukin-1 [IL-1], IL-6, IL-8, IL-10, IL-12, gamma interferon [IFN-gamma], interferon-inducible protein [IP-10], and monocyte chemotactic protein 1 [MCP-1]) with the clinical response to 2 months of intensive therapy. From January to December 2007, 40 M. tuberculosis-infected patients and 40 healthy patients were recruited. After exclusion for diabetes, 32 patients and 36 controls were analyzed. The clinical responses of the M. tuberculosis-infected patients on the basis of the findings of chest radiography were compared to their plasma cytokine levels measured before and after 2 months of intensive anti-M. tuberculosis therapy and 6 months of therapy with human cytokine antibody arrays. Chest radiographs of 20 of 32 M. tuberculosis-infected patients showed improvement after 2 months of intensive therapy (early responders), while the M. tuberculosis infections in 12 of 32 of the patients resolved after a further 4 months (late responders). The levels of expression of TNF-alpha, MCP-1, IFN-gamma, and IL-1beta were decreased; and the level of IL-10 increased in early responders. After adjustment for age, gender, and the result of sputum culture for M. tuberculosis, significant differences in the levels of MCP-1 and IP-10 expression were observed between the early and the late responders after 2 months of intensive anti-M. tuberculosis therapy. Due to the interpatient variability in IP-10 levels, intrapatient monitoring of IP-10 levels may provide more insight into the M. tuberculosis responder status than comparison between patients. Plasma MCP-1 levels were normalized in patients who had resolved their M. tuberculosis infections. Further studies to evaluate the association of the modulation in MCP-1 levels with early and late responses are warranted.
结核分枝杆菌感染是一个重大的全球健康问题。早期识别对抗结核治疗反应不佳的高危患者,将有助于阐明抗结核反应中的关键因素。本研究的目的是将细胞因子表达(白细胞介素-1 [IL-1]、IL-6、IL-8、IL-10、IL-12、γ干扰素 [IFN-γ]、干扰素诱导蛋白 [IP-10] 和单核细胞趋化蛋白1 [MCP-1])的调节与强化治疗2个月后的临床反应相关联。2007年1月至12月,招募了40例结核分枝杆菌感染患者和40例健康患者。排除糖尿病患者后,对32例患者和36例对照进行了分析。根据胸部X线检查结果,将结核分枝杆菌感染患者的临床反应与其在强化抗结核治疗2个月前后及6个月治疗后用人细胞因子抗体阵列检测的血浆细胞因子水平进行比较。32例结核分枝杆菌感染患者中有20例在强化治疗2个月后胸部X线片显示改善(早期反应者),而32例患者中有12例在再过4个月后结核分枝杆菌感染得到解决(晚期反应者)。早期反应者中肿瘤坏死因子-α、MCP-1、IFN-γ和IL-1β的表达水平降低;IL-10水平升高。在调整年龄、性别和结核分枝杆菌痰培养结果后,强化抗结核治疗2个月后,早期和晚期反应者之间MCP-1和IP-10表达水平存在显著差异。由于患者间IP-10水平存在差异,对患者个体进行IP-10水平监测可能比患者间比较更能深入了解结核分枝杆菌反应者状态。结核分枝杆菌感染已得到解决的患者血浆MCP-1水平恢复正常。有必要进一步开展研究,以评估MCP-1水平调节与早期和晚期反应之间的关联。